Skip to main content

Table 2 Pharmacokinetic data: mean levels of Posiphen (ng/mL) averaged over 24 h of CSF sampling

From: A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with early Alzheimer’s Disease

 

Treatment arm

 

60 mg (n = 5)

60 mg BID (n = 5)

60 mg TID (n = 1)

Plasma

Posiphen

7.16 ± 4.25

9.51 ± 5.77

12.01

N1

1.29 ± 0.77

3.02 ± 1.40

2.51

N8

2.25 ± 1.36

5.04 ± 1.80

3.35

CSF

Posiphen

0.46 ± 0.30

0.73 ± 0.53

0.71

N1

0.02 ± 0.04

0.28 ± 0.30

0.00

N8

0.35 ± 0.26

0.77 ± 0.43

0.15

Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193